In the past 52-week period, shares of Clovis Oncology, Inc. (NASDAQ:CLVS) have moved within the range of $25.81 to $99.45. On the stock’s most recent trading day, the company’s shares ended the regular session at $76.63, which is 22.95% lower than its 52-week high.
Clovis Oncology, Inc. (CLVS) has demonstrated a 20-day simple moving average (SMA) of -5.38%, and a 50-day SMA of 0.50%. This public company’s current market capitalization stands at $3.71 billion.
Analyzing Consensus Estimates, Sales Revenue and Net Income
Checking the amount of enthusiasm that Wall Street analysts hold for a particular stock is crucial when thinking about entering a position. According to the latest data, the consensus recommendation for Clovis Oncology, Inc. (CLVS) is Outperform.
Public companies normally post earnings and revenue results that fall somewhat above or below the average Wall Street estimate. In the most recent quarterly financial report, for the quarter ending Jun. 2017, Clovis Oncology, Inc. (CLVS) delivered a 9.84% surprise with its net revenue. Sales reached $0.01 billion during the three-month period, compared to the average analyst estimate of $0.01 billion.
Meanwhile, during the same quarter Clovis Oncology, Inc. (CLVS) delivered a -39.56% earnings surprise. Net earnings for the quarter were posted at -$1.29 per share, whereas Wall Street had forecast -$2.13 per share.
Ownership at Clovis Oncology, Inc. (CLVS), According to Most Recent SEC Filings
A publicly-traded organization’s latest 13F filings tell us important details about its institutional ownership. Clovis Oncology, Inc. (CLVS) has 0.05 billion shares outstanding currently, 99.85% of which belong to institutional investors. Those institutional holdings amount to $3.69 billion.
Additionally, according to the most recent 13F filing from Clovis Oncology, Inc. (CLVS), there were 70 new positions totaling 5,054,427 shares of the company’s stock. There were 35 sold out positions, on the other hand, totaling 3,036,757 shares.
Short, Medium and Long Term Indicators
Assessing the average trade volume of a public company’s stock in the short, medium and long term is helpful to gain an understanding of trading activity and investor sentiment. Clovis Oncology, Inc. (CLVS) has had a 20-day average volume of 1,218,925 shares, with an average of 40% of short term indicators pointed at Sell.
The stock’s 50-day average volume has been 1,485,024 shares, with an average of 25% of medium term indicators pointing toward Buy. Finally, its 100-day average volume is 1,779,676 shares with 67% of long-term indicators pointing to Sell.